Cirrhosis as new indication for statins
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
In the recent years, there have been an increasing number of reports on favourable effects of statins in patients with advanced chronic liver disease. These include reduction in portal pressure, improved liver sinusoidal endothelial and hepatic microvascular dysfunction, decreased fibrogenesis, protection against ischaemia/reperfusion injury, safe prolongation of ex vivo liver graft preservation, reduced sensitivity to endotoxin-mediated liver damage, protection from acute-on-chronic liver failure, prevention of liver injury following hypovolaemic shock and preventing/delaying progression of cirrhosis of any aetiology. Moreover, statins have been shown to have potential beneficial effects in the progression of other liver diseases, such as chronic sclerosing cholangitis and in preventing hepatocellular carcinoma. Because of these many theoretically favourable effects, statins have evolved from being considered a risk to kind of wonder drugs for patients with chronic liver diseases. The present article reviews the current knowledge on the potential applications of statins in chronic liver diseases, from its mechanistic background to objective evidence from clinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
de Lemos, J. A., Blazing, M. A., Wiviott, S. D., Lewis, E. F., Fox, K. A. A., White, H. D., Rouleau, J.-L., Pedersen, T. R., Gardner, L. H., Mukherjee, R., et al. (2004) · JAMA · doi:10.1001/jama.292.11.1307 · Cited by 1,333
Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.027 · Cited by 1,067
Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group (2010) · The Lancet · doi:10.1016/s0140-6736(10)60310-8 · Cited by 558
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6476a · Cited by 438
Statin use and non-alcoholic steatohepatitis in at risk individuals
Dongiovanni, P., Petta, S., Mannisto, V., Mancina, R. M., Pipitone, R., Karja, V., Maggioni, M., Kakela, P., Wiklund, O., Mozzi, E., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.006 · Cited by 390
Abraldes, J. G., Villanueva, C., Aracil, C., Turnes, J., Hernandez-Guerra, M., Genesca, J., Rodriguez, M., Castellote, J., García-Pagán, J. C., Torres, F., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.004 · Cited by 339
Self-citationMarrone, G., Maeso-Díaz, R., García-Cardena, G., Abraldes, J. G., García-Pagán, J. C., Bosch, J., & Gracia-Sancho, J. (2015) · Gut · doi:10.1136/gutjnl-2014-308338 · Cited by 222
Self-citationPose, E., Napoleone, L., Amin, A., Campion, D., Jimenez, C., Piano, S., Roux, O., Uschner, F. E., de Wit, K., Zaccherini, G., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30320-6 · Cited by 154
Cited by
Ginès, P., Krag, A., Abraldes, J. G., Solà, E., Fabrellas, N., & Kamath, P. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01374-x · Cited by 1,663
Role of liver sinusoidal endothelial cells in liver diseases
Gracia-Sancho, J., Caparrós, E., Fernández-Iglesias, A., & Francés, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00411-3 · Cited by 410
Self-citationEngelmann, C., Clària, J., Szabo, G., Bosch, J., & Bernardi, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.002 · Cited by 400
Self-citationAlcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease
Åberg, F., Byrne, C. D., Pirola, C. J., Männistö, V., & Sookoian, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.08.030 · Cited by 307
Zhang, L.-F., Wang, X.-H., Zhang, C.-L., Lee, J., Duan, B.-W., Xing, L., Li, L., Oh, Y.-K., & Jiang, H.-L. (2022) · ACS Nano · doi:10.1021/acsnano.2c03858 · Cited by 92
Metadata
- Authors
- Bosch, J., Gracia-Sancho, J., & Abraldes, J. G.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2020-03-05
- Volume
- 69
- Issue
- 5
- Pages
- 953-962
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W3010121905
- Cited by
- 141
- References
- 10
- FWCI
- 10.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cirrhosis as new indication for statins. https://app.cochat.ai/papers/10.1136/gutjnl-2019-318237
- The paper
- Bosch, J., Gracia-Sancho, J., & Abraldes, J. G. (2020). Cirrhosis as new indication for statins. Gut. https://doi.org/10.1136/gutjnl-2019-318237
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.